Rockwell Medical Inc (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for …
On June 22, Brean Capital analyst Jonathan Aschoff weighed in on Keryx Biopharmaceuticals (NASDAQ:KERX) and Rockwell Medical Inc (NASDAQ:RMTI) to provide commentary on …
Oppenheimer analyst Ling Wang weighed in today with a few insights on Rockwell Medical Inc (NASDAQ:RMTI), after having a meeting with CEO Robert Chioini and …
Oppenheimer analyst Ling Wang weighed in with a favorable report on shares of Rockwell Medical Inc (NASDAQ:RMTI), as the company plans to launch Triferic, a …
Rockwell Medical Inc (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services …
In a research report published Friday, Brean Capital analyst Jonathan Aschoff maintained a Sell rating on Rockwell Medical Inc (NASDAQ:RMTI) with a $4.00 price target, …
